First Seizure Evaluation
The evaluation of a patient presenting with a first seizure is one of the most common and consequential clinical scenarios in neurology. The initial assessment must accomplish several goals simultaneously: determine whether the event was an epileptic seizure, distinguish provoked (acute symptomatic) from unprovoked seizures, identify immediate threats requiring emergent intervention, estimate the risk of seizure recurrence, and guide the decision of whether to initiate long-term antiseizure medication. A systematic approach that integrates clinical history, targeted laboratory testing, EEG, and neuroimaging forms the foundation for accurate diagnosis and appropriate management.
Bottom Line
- Acute symptomatic (provoked) seizures occur within 7 days of an acute brain insult or systemic disturbance and generally do not require long-term antiseizure medication
- After a single unprovoked seizure, the overall recurrence risk is approximately 40–50% within 2 years; however, this risk rises to ≥60% when an epileptiform EEG abnormality, structural brain lesion, or nocturnal seizure is present
- EEG is the single most useful ancillary test in the evaluation of a first seizure — epileptiform discharges are found in approximately 20–50% of patients with a first unprovoked seizure on initial routine EEG
- MRI with epilepsy protocol is the preferred neuroimaging modality; CT is appropriate emergently but insufficient for definitive evaluation
- Treatment after a first seizure reduces recurrence risk by approximately 35% but does not alter the long-term prognosis of epilepsy; the decision to treat should be individualized
- The differential diagnosis includes syncope (most common mimic), psychogenic nonepileptic seizures, parasomnias, movement disorders, and migraine — misdiagnosis of epilepsy occurs in up to 20–25% of cases
- Driving restrictions vary by jurisdiction but most US states require a seizure-free interval of 3–12 months (commonly 6 months)
Acute Symptomatic vs. Unprovoked Seizures
The critical first distinction in first seizure evaluation is whether the seizure was acute symptomatic (provoked) or unprovoked, as this fundamentally changes management and prognosis.
| Feature | Acute Symptomatic (Provoked) | Unprovoked |
|---|---|---|
| Definition | Seizure occurring within 7 days of an acute brain insult or systemic disturbance | Seizure occurring in the absence of an identifiable acute trigger or >7 days after a brain insult |
| Common causes | Alcohol withdrawal, metabolic derangements (hyponatremia, hypoglycemia, uremia), acute stroke, CNS infection, traumatic brain injury, drug toxicity | Remote structural lesion, idiopathic/genetic factors, remote CNS infection, unknown cause |
| Recurrence risk | 3–10% over 10 years (if provoked factor is corrected) | 40–50% over 2 years (overall); ≥60% with EEG abnormality or structural lesion |
| Long-term ASM | Generally not indicated; treat the underlying cause | Consider based on recurrence risk; mandatory if meets epilepsy definition |
| Diagnosis of epilepsy? | No — provoked seizures do not count toward epilepsy diagnosis | One unprovoked seizure + ≥60% recurrence risk = epilepsy diagnosis per ILAE |
An important exception applies to infectious and parasitic diseases, where acute symptomatic seizures can persist beyond the conventional 7-day window due to persistent brain inflammation. Notably, in patients with viral encephalitis, the presence of acute symptomatic seizures increases the likelihood of developing epilepsy by 22-fold.
Red Flags Requiring Emergent Evaluation
- Persistent altered mental status that does not improve within 30–60 minutes post-seizure — consider ongoing nonconvulsive status epilepticus, structural pathology, or metabolic emergency
- Focal neurologic deficits beyond transient Todd paralysis — may indicate acute stroke, intracranial hemorrhage, or mass lesion
- Fever with seizure in adults — raises concern for CNS infection (meningitis, encephalitis); lumbar puncture may be warranted
- History of cancer — new seizure may be the first presentation of brain metastasis or leptomeningeal disease
- Immunocompromised patient — broader infectious differential including toxoplasmosis, progressive multifocal leukoencephalopathy, CMV encephalitis
- Anticoagulation or coagulopathy — risk of intracranial hemorrhage as the precipitant
- Pregnancy — consider eclampsia, posterior reversible encephalopathy syndrome (PRES), or cerebral venous thrombosis
- Seizure in the setting of recent head trauma — urgent neuroimaging required to exclude epidural or subdural hematoma
Clinical Assessment
The clinical history is the most important element in first seizure evaluation. Since the patient is often amnestic to the event, witness descriptions are invaluable and should be actively sought. The assessment should systematically address:
Pre-Ictal History
- Triggers and circumstances — sleep deprivation, alcohol use or withdrawal, drug use, missed medications, illness, metabolic disturbance, photic stimulation
- Warning signs (aura) — any subjective experience immediately before the event; character of the aura has localizing value
- Activity at onset — was the patient awake or asleep? Standing, sitting, or supine? Exerting themselves?
- Positional context — events occurring during prolonged standing or in hot environments raise suspicion for syncope
Ictal Description
- Onset pattern — was there focal onset (head turning, unilateral jerking, aura) before bilateral involvement?
- Motor features — tonic stiffening, clonic jerking, automatisms, hyperkinetic movements; bilateral or unilateral?
- Duration — most epileptic seizures last 1–3 minutes; events lasting >5 minutes raise concern for status epilepticus; very prolonged events (>10–15 minutes) raise suspicion for nonepileptic episodes
- Awareness — was the patient responsive during the event?
- Incontinence — occurs in both seizures and syncope; not specific for either
- Tongue bite — lateral tongue bite has high specificity for generalized tonic-clonic seizures; tip-of-tongue bite is nonspecific
Post-Ictal Findings
- Confusion — postictal confusion lasting minutes is characteristic of seizure; immediate return to baseline raises suspicion for syncope
- Focal deficits — Todd paralysis (postictal focal weakness), postictal aphasia
- Somatic injury — posterior shoulder dislocation, vertebral compression fractures, oral lacerations
- Muscle soreness — generalized myalgias from tonic-clonic activity
Relevant Medical History
Certain risk factors predispose to epilepsy and should be specifically queried:
- History of febrile seizures (especially complex febrile seizures)
- Prior traumatic brain injury
- Prior meningitis or encephalitis
- Cerebrovascular disease (stroke, vascular malformations)
- Family history of epilepsy
- History of brain tumors or neurosurgery
- Neurodevelopmental disorders
- Prior similar episodes that may have gone unrecognized (eg, absence seizures, myoclonic jerks, nocturnal events)
Clinical Pearl: Uncovering Prior Seizures
- Carefully reviewing the history of a patient presenting with a "first seizure" may reveal prior similar episodes that were not recognized as seizures
- Ask specifically about: brief staring episodes (absence seizures), morning myoclonic jerks (JME), nocturnal events (frontal lobe seizures), déjà vu episodes with impaired awareness (temporal lobe seizures)
- When evaluating a 17-year-old with a new-onset GTC seizure, prior staring episodes suggestive of absence seizures or myoclonic jerking could provide supportive evidence for underlying idiopathic generalized epilepsy
- Discuss with family members or caregivers — patients often do not disclose or recognize these events as abnormal
Diagnostic Workup
Laboratory Testing
Initial laboratory evaluation serves primarily to identify provoked (acute symptomatic) seizures that require correction of the underlying cause rather than long-term antiseizure medication.
| Test | Purpose | Key Thresholds / Notes |
|---|---|---|
| Complete blood count | Infection screening; baseline before starting ASMs | Leukocytosis may suggest infection or postictal stress response |
| Basic metabolic panel | Electrolyte abnormalities (Na, Ca, Mg, glucose) | Sodium <120 mEq/L, glucose <40 mg/dL, calcium <7 mg/dL — common provoked seizure thresholds |
| Blood glucose | Hypoglycemia or hyperglycemia | Hypoglycemia is a common and reversible cause of seizures |
| Serum calcium / magnesium | Hypocalcemia, hypomagnesemia | Low magnesium may also lower seizure threshold |
| Hepatic / renal function | Uremia, hepatic encephalopathy | Relevant for ASM dosing if treatment initiated |
| Toxicology screen | Drug intoxication or withdrawal | Cocaine, amphetamines, synthetic cannabinoids; alcohol level |
| Serum prolactin | Elevated 10–20 minutes post-seizure (GTC or focal impaired awareness) | Sensitivity is limited; primarily useful to distinguish epileptic GTC from PNES; must be drawn within 20 minutes |
| Lumbar puncture | If CNS infection or autoimmune encephalitis is suspected | Fever, immunocompromised status, meningismus, or persistent altered mental status |
Electroencephalography (EEG)
EEG is the single most useful ancillary test in first seizure evaluation. It serves three primary purposes: (1) supporting the diagnosis that the event was an epileptic seizure, (2) classifying the seizure and epilepsy type (focal vs. generalized), and (3) identifying a specific epilepsy syndrome when possible.
- Timing matters: EEG yield is highest when performed within 24–48 hours of the seizure; the sensitivity of a routine EEG for detecting epileptiform discharges after a first seizure is approximately 20–50%
- Sleep recording increases yield: Sleep deprivation and recording during sleep increases the detection of epileptiform discharges, as many patterns are activated during drowsiness and sleep
- Normal EEG does not exclude epilepsy: Epilepsy is a clinical diagnosis — an EEG showing epileptiform discharges is not required for establishing the diagnosis if the clinical presentation is convincing
- Prolonged or ambulatory EEG: If the routine EEG is non-diagnostic but clinical suspicion remains high, prolonged or ambulatory EEG monitoring (24–72 hours) increases the diagnostic yield
- Epileptiform discharges after a first seizure significantly increase the recurrence risk and may be sufficient to diagnose epilepsy after a single unprovoked seizure (when recurrence risk exceeds 60%)
Clinical Pearl: EEG Interpretation Caveats
- EEG is a supportive test, not a definitive diagnostic test — if there is strong clinical suspicion of an epileptic seizure, the diagnosis can be made irrespective of EEG results
- Epileptiform discharges can occur in 0.5–2% of the general population without epilepsy — they must be interpreted in clinical context
- Conversely, up to 50% of patients with epilepsy may have a normal initial routine EEG
- Certain normal variants (wicket spikes, benign epileptiform transients of sleep, small sharp spikes) are commonly misread as epileptiform and lead to misdiagnosis
- If a specific epilepsy syndrome is suspected (eg, JME), EEG should include hyperventilation and photic stimulation to maximize sensitivity
Neuroimaging
Neuroimaging is recommended for all patients with spontaneous (unprovoked) seizures, particularly if they exhibit focal electroclinical features. The goals are to identify structural etiologies (stroke, tumor, mesial temporal sclerosis, cortical dysplasia, vascular malformations) and guide prognosis and management.
| Modality | Strengths | Limitations | When to Use |
|---|---|---|---|
| Non-contrast CT | Rapid; widely available; detects hemorrhage, calcified lesions, large mass lesions, skull defects | Poor sensitivity for subtle structural abnormalities (cortical dysplasia, hippocampal sclerosis, small tumors) | Emergency setting; first-time seizure workup; when MRI is contraindicated or unavailable |
| MRI with epilepsy protocol | Superior sensitivity for hippocampal sclerosis, cortical dysplasia, low-grade tumors, vascular malformations, subtle structural abnormalities | Longer acquisition time; less available in resource-limited settings; may require sedation | All patients with suspected focal epilepsy; definitive imaging for all first seizure evaluations when possible; minimum 1.5 Tesla recommended |
In certain clinical scenarios, neuroimaging may not be necessary — particularly in children presenting with specific clinical and EEG patterns such as those with typical idiopathic generalized epilepsy syndromes. However, because the majority of spontaneous seizures in adults are focal, imaging should be considered for all adult patients with a first seizure.
Risk of Recurrence After First Seizure
Understanding the risk of seizure recurrence is central to the decision of whether to initiate antiseizure medication after a first unprovoked seizure.
| Risk Factor | Impact on Recurrence Risk | Estimated Risk |
|---|---|---|
| No identified risk factors | Baseline risk | ~40–50% over 2 years |
| Epileptiform EEG abnormality | Substantially increases risk; may exceed 60% threshold for epilepsy diagnosis | ~60–70% over 2 years |
| Structural brain lesion (prior stroke, TBI, tumor) | Substantially increases risk; concordant with seizure semiology = high risk | ~60–70% over 2 years |
| Nocturnal seizure (during sleep) | Increases risk compared to daytime seizure | Higher than baseline |
| Prior brain insult >7 days before seizure | Remote symptomatic seizure; increased recurrence risk | ~50–65% over 2 years |
| Family history of epilepsy | Modest increase in risk | Modestly above baseline |
| Abnormal neurologic examination | Suggests underlying structural or neurodevelopmental etiology | Increased above baseline |
| Two or more risk factors combined | Cumulative increase; often exceeds 60% threshold | ≥60% over 2 years |
The ILAE practical definition of epilepsy allows diagnosis after a single unprovoked seizure when the estimated recurrence risk is at least 60% over the next 10 years, similar to the recurrence risk after two unprovoked seizures. This threshold is typically met when an epileptiform EEG abnormality, a concordant structural brain lesion, or identification of an epilepsy syndrome is present.
When to Start Treatment After First Seizure
The decision to initiate antiseizure medication (ASM) after a first unprovoked seizure is one of the most important decisions in epilepsy management and should be individualized based on recurrence risk, patient preferences, and risk-benefit analysis.
Evidence from Key Trials
The landmark FIRST (First Seizure Trial) and MESS (Multicentre trial of Early Epilepsy and Single Seizures) trials established that:
- Immediate treatment after a first seizure reduces the risk of seizure recurrence by approximately 35% over 2 years
- However, immediate treatment does not alter the long-term remission rate at 5 years — patients who defer treatment until a second seizure achieve the same long-term seizure control
- This means that early treatment delays the second seizure but does not change whether the patient ultimately achieves seizure freedom
Indications Favoring Immediate Treatment
- Recurrence risk ≥60% (meets ILAE definition of epilepsy after a single seizure)
- Epileptiform EEG abnormalities
- Structural brain lesion concordant with seizure type
- Nocturnal seizure with high risk of injury
- Patient occupation or activities where seizure recurrence poses significant safety risk (eg, commercial driving, working at heights)
- Patient preference after understanding risks and benefits
- Identification of an epilepsy syndrome (eg, JME presenting with a first GTC but with preceding myoclonic jerks)
Situations Favoring Deferral of Treatment
- Low recurrence risk (normal EEG, normal MRI, no risk factors)
- Acute symptomatic seizure with correctable cause
- Patient preference to observe after informed discussion
- Concerns about medication side effects (teratogenicity in women of childbearing potential, cognitive effects, drug interactions)
- Uncertainty about whether the event was truly an epileptic seizure
Clinical Pearl: Shared Decision-Making
- The decision to treat or defer after a first seizure should involve a thorough discussion with the patient about recurrence risk, driving implications, safety risks, and medication side effects
- Present the evidence clearly: treatment reduces recurrence risk in the short term but does not change the long-term outcome
- For patients who defer treatment, establish a clear plan for follow-up and for what to do if a second seizure occurs
- Document the discussion and the patient's informed decision in the medical record
Driving Restrictions After First Seizure
Driving restrictions after a first seizure are governed by state or jurisdictional regulations and are an important practical consideration for patients. Key points include:
- Most US states require a seizure-free interval of 3 to 12 months before driving privileges are restored; the most common requirement is 6 months
- Commercial driving (CDL holders) typically has more stringent requirements, often requiring longer seizure-free intervals and, in some jurisdictions, freedom from antiseizure medications
- Physician reporting varies by state — some states have mandatory reporting laws, while others rely on patient self-reporting
- Provoked seizures may have different driving implications than unprovoked seizures in some jurisdictions, particularly if the provoking factor has been corrected
- Clinicians should document the driving restriction discussion and refer patients to their state's Department of Motor Vehicles for specific regulations
Differential Diagnosis
Misdiagnosis of epilepsy occurs in approximately 20–25% of cases. A careful differential diagnosis is essential before committing a patient to a lifetime diagnosis of epilepsy and long-term medication use.
| Condition | Key Distinguishing Features | Diagnostic Approach |
|---|---|---|
| Syncope (convulsive syncope) | Provoked by prolonged standing, pain, or Valsalva; brief myoclonic jerks possible during syncope; rapid return to baseline (<1 min); pallor at onset; no lateral tongue bite; no postictal confusion beyond brief seconds | Tilt-table testing; cardiac evaluation (ECG, Holter); witness history distinguishes from epileptic seizure |
| Psychogenic nonepileptic seizures (PNES) | Variable semiology between events; prolonged duration (>5 min); waxing/waning pattern; eyes typically closed; preserved pupillary reflexes; resistance to passive eye opening; pelvic thrusting (can also occur in frontal seizures); no postictal confusion | Video-EEG monitoring (gold standard); normal ictal EEG during typical event; serum prolactin normal |
| Transient ischemic attack (TIA) | Sudden onset of focal neurologic symptoms (weakness, speech difficulty, visual loss) that resolve within 24 hours, usually within 30–60 minutes; typically negative symptoms (loss of function) rather than positive symptoms (jerking, tingling) | Vascular imaging (CT angiography, MR angiography); diffusion-weighted MRI; cardiac evaluation |
| Migraine with aura | Visual aura evolves slowly over 5–60 minutes (vs. seconds for seizure); typically followed by headache; zigzag/fortification spectra rather than colored circles; no impaired awareness or motor convulsion | Clinical history; ICHD-3 criteria; seizures and migraine can coexist (migralepsy is rare) |
| Parasomnias | Complex behaviors during sleep (sleepwalking, sleep terrors, REM behavior disorder); variable semiology; typically arise from specific sleep stages; no epileptiform discharges on EEG | Polysomnography with video; sleep-related hypermotor epilepsy can closely mimic parasomnias and requires video-EEG for differentiation |
| Movement disorders | Paroxysmal dyskinesias (paroxysmal kinesigenic dyskinesia, paroxysmal nonkinesigenic dyskinesia); tics; myoclonus of non-epileptic origin; preserved awareness; stereotyped but triggered by specific stimuli | Clinical history; genetic testing (PRRT2 for PKD); normal EEG |
| Panic attacks | Intense fear with palpitations, sweating, trembling, dyspnea; builds over minutes (vs. seconds for ictal fear); no impaired awareness; no automatisms or motor convulsion; responsive to anxiolytics | Clinical history; psychiatric evaluation; consider ictal fear if episodes are stereotyped and brief (<2 min) |
Pitfalls in First Seizure Diagnosis
- Convulsive syncope is often misdiagnosed as epilepsy: Brief myoclonic jerks during syncope (from cerebral hypoperfusion) occur in up to 10–15% of syncope episodes and do not indicate epilepsy; the jerks are typically brief (a few seconds), irregular, and asymmetric
- A lateral tongue bite has high specificity for generalized tonic-clonic seizures and is one of the most reliable clinical features distinguishing seizures from syncope; tip-of-tongue bites are nonspecific
- Incontinence alone is not diagnostic: Urinary incontinence occurs in both seizures and syncope and should not be used as a sole discriminating factor
- Starting ASMs without adequate evaluation: Initiating long-term ASM therapy before a complete workup (including EEG and ideally MRI) can commit a patient to unnecessary treatment — except in situations requiring emergent seizure control
- Misinterpretation of EEG: Normal EEG variants misread as epileptiform discharges are a leading cause of epilepsy misdiagnosis; ensure EEG interpretation by qualified neurophysiologists
- Failure to consider autoimmune etiologies: In patients with new-onset seizures and encephalopathic features, autoimmune encephalitis (NMDA receptor, LGI1, GAD) should be considered; early immunotherapy is the recommended treatment
Physical Examination Considerations
While the neurologic examination may be normal in many patients presenting with a first seizure, several findings warrant careful attention:
- Dysmorphic features — may suggest a genetic syndrome associated with epilepsy (eg, tuberous sclerosis, neurofibromatosis)
- Cutaneous manifestations — ash-leaf spots, shagreen patches, or facial angiofibromas suggest tuberous sclerosis; café-au-lait spots suggest neurofibromatosis
- Focal neurologic impairments — hemiparesis, visual field deficits, or hemispatial neglect suggest an underlying structural abnormality
- Papilledema — raises concern for increased intracranial pressure (mass lesion, venous thrombosis)
- Tongue laceration — lateral tongue bite supports the diagnosis of GTC seizure
- Todd paralysis — transient postictal focal weakness indicates focal seizure with contralateral hemisphere onset; typically resolves within minutes to hours
Approach to New-Onset Seizures: A Diagnostic Algorithm
Stepwise First Seizure Evaluation
- Step 1 — Was this an epileptic seizure? Obtain detailed witness and patient history; distinguish from syncope, PNES, TIA, migraine, parasomnia, and movement disorders
- Step 2 — Is this provoked or unprovoked? Review labs, toxicology, and clinical context; identify and correct acute symptomatic causes
- Step 3 — Classify the seizure type. Apply the ILAE 2017 framework: focal vs. generalized vs. unknown onset; motor vs. nonmotor; awareness level
- Step 4 — Obtain EEG. Ideally within 24–48 hours; include sleep recording; interpret in clinical context
- Step 5 — Obtain neuroimaging. CT emergently if indicated; MRI with epilepsy protocol for definitive evaluation of all adults with a first unprovoked seizure
- Step 6 — Assess recurrence risk. Integrate EEG findings, imaging results, clinical history, and examination findings to estimate recurrence risk
- Step 7 — Determine epilepsy type and syndrome. If sufficient information is available, classify the epilepsy type (focal, generalized, combined, unknown) and identify any specific syndrome
- Step 8 — Investigate etiology. Structural, genetic, infectious, metabolic, immune, or unknown; additional testing (genetic, antibodies, metabolic) as indicated
- Step 9 — Shared decision-making regarding treatment. Discuss recurrence risk, treatment benefits and risks, driving restrictions, and safety precautions
- Step 10 — Safety counseling and follow-up. Driving restrictions, water safety, heights, seizure first aid, SUDEP education (if applicable), and follow-up plan
Special Populations
Elderly Patients
Cerebrovascular disease is the most frequent cause of late-onset epilepsy in adults, with Alzheimer disease and other neurodegenerative disorders also contributing significantly to the development of late-onset epilepsy. In elderly patients with a first seizure:
- MRI is particularly important to evaluate for stroke, tumor, and neurodegenerative changes
- Subtle focal seizures may present as recurrent confusional episodes or transient cognitive impairment
- Drug interactions and side effect profiles are important considerations when selecting ASMs in the elderly
- Lower starting doses are generally appropriate due to altered pharmacokinetics
Children
In children, the diagnostic approach differs in several ways:
- Febrile seizures are the most common childhood seizure type and are distinct from epilepsy; complex febrile seizures carry a higher risk of subsequent epilepsy
- Specific electroclinical syndromes (childhood absence epilepsy, SeLECTS) have characteristic presentations that may not require MRI if the clinical and EEG picture is classic
- Inborn metabolic disorders remain important considerations in children presenting with seizures and should prompt early evaluation
- Genetic testing may be particularly valuable in children with unexplained epilepsy, especially when developmental concerns are present
References
- Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475–482.
- Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):522–530.
- Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58(4):512–521.
- Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705–1713.
- Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1475–1499.
- Nascimento FA, Friedman D, Peters JM, et al. Focal epilepsies: update on diagnosis and classification. Epileptic Disord 2023;25(1):1–17.
- Yacubian EMT, Kakooza-Mwesige A, Singh G, et al. Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy. Epileptic Disord 2022;24(6):994–1019.
- Almannai M, Al Mahmoud RA, Mekki M, El-Hattab AW. Metabolic seizures. Front Neurol 2021;12:640371.
- Ricci L, Boscarino M, Assenza G, et al. Clinical utility of home videos for diagnosing epileptic seizures: a systematic review and practical recommendations. Neurol Sci 2021;42(4):1301–1309.
- Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood. Epilepsia 2022;63(6):1398–1442.
- Sveinsson O, Andersson T, Mattsson P. Clinical risk factors in SUDEP: a nationwide population-based case-control study. Neurology 2020;94(4).
- Skidmore CT. Neuroimaging in epilepsy. Continuum (Minneap Minn) 2025;31(1, Epilepsy):61–80.
- Fisher RS, Cross JH, D'Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017;58(4):531–542.
- Scheffer IE, French J, Hirsch E, et al. Classification of the epilepsies: new concepts for discussion and debate. Epilepsia Open 2016;1(1-2):37–44.
- Beniczky S, Tatum WO, Blumenfeld H, et al. Seizure semiology: ILAE glossary of terms and their significance. Epileptic Disord 2022;24(3):447–495.